GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

May 31, 2007

Conditions
Postoperative SedationIntubationRespiration, Artificial
Interventions
DRUG

AQUAVAN (fospropofol disodium; GPI 15715 )

Trial Locations (17)

10016

New York University School of Medicine, New York

10029

Mount Sinai School of Medicine, New York

10467

Montefiore Medical Center, The Bronx

11040

Long Island Jewish Medical Center, New Hyde Park

27157

Wake Forest University Baptist Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

33136

Jackson Memorial Hospital, Miami

37232

Vanderbilt University Medical Center, Nashville

48202

Henry Ford Hospital, Detroit

52242

University of Iowa Hospital and Clinics, Iowa City

60068

Advocate Lutheran General Hospital, Park Ridge

72756

St. Mary's Hospital, Rogers

73104

Oklahoma University Medical Center, Oklahoma City

75216

Department of Veterans Affairs, North Texas Health Care System, Dallas

04210

Central Maine Pulmonary Associates, Auburn

02118

Boston Medical Center, Boston

08103

Cooper University Hospital, Camden

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00125398 - GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting | Biotech Hunter | Biotech Hunter